Pancreatic ductal adenocarcinoma (PDAC) represents the seventh leading cause of cancer-related death in the world, with an overall 5-year survival rate of 5%. Even localized disease has a 5-year survival rate of only 20%–25% [
1]. In contrast to declining trends for other major cancers, death rates are rising in both sexes for PDAC [
2]. This malignancy is often diagnosed in an advanced stage, leaving only palliative treatment options [
3]. A growing number of studies has considerably improved our knowledge concerning the genetic and epigenetic alterations, the molecular perturbances and the precursor lesions, associated with the onset and the development of this malignancy [
4‐
6]. In particular, changes in telomere length, complex karyotypes and multiple copy number alterations often spanning very large genomic regions, as well as several DNA changes have been reported [
3,
7]. The latter consists of activating mutations in oncogenes, such as
KRAS, or inactivating alterations in tumor suppressor genes, including
P16,
TP53, and
SMAD4 or in additional genes, such as
MLL3,
TGFBR2,
ARID1A,
CDKN2a and
ATM [
8]. These mutations, observed in non-invasive precursor lesions known as pancreatic intraepithelial neoplasia (PanIN) [
9,
10], accumulate and drive neoplastic transformation and tumor progression [
9,
11,
12]. However, despite these apparently encouraging results, this type of approach has produced no significant impact on the prognosis of PDAC [
13]. Therefore, novel pathogenetic models are needed to explain the aggressive biological behavior, and dismal outcome of this malignancy as well as to suggest new and more effective options for its diagnosis and therapy [
14]. Accumulating data indicate that not only alterations in malignant epithelial cells, but also extracellular matrix, surrounding cancerous cells play a critical, dynamic and cooperative role in the development of inflammatory as well as cancerous lesions [
15,
16]. Histologically, PDAC is a complex structure, composed of infiltrating neoplastic glands embedded in an intense desmoplastic reaction. The latter consists of an ECM, non-neoplastic activated fibroblasts [
17], myofibroblasts, cells of the immune system [
18,
19], blood and lymphatic vessels. ECM includes collagens, non-collagen glycoproteins, glycosaminoglycans, growth factors and proteoglycans as well as modulators of the cell matrix interaction such as periostin, tenascin C, SPARC (secreted protein acidic and rich in cysteine) and thrombospondin [
20,
21]. This framework represents the bulk of the cancer mass [
22]. Interactions between the neoplastic and non-neoplastic cells and ECM have been proposed to stimulate the extensive desmoplastic reaction [
23‐
26]. Although a critical role of stroma in pancreatic carcinogenesis had been recognized for many years, only recently the study of this crucial tissue component has gained a considerable interest and has been considered in clinical practice [
14,
27].
There is accumulating evidence that while natural stroma can delay or prevent tumorigenesis, abnormal ECM components can promote tumor growth, and that this explains the low therapeutic response of pancreatic cancer patients [
20,
28]. The complex interplay between tumor cells, non-tumoral cells and their ECM products also leads to dynamical changes in the transcriptional program of the cellular components, such as activated fibroblasts, stellate cells and inflammatory cells, which in turn promotes cancer cell motility, resistance to hypoxia and stromal neo-vascularity [
29]. To date, mechanisms involved in the initiation and progression of these events are not completely understood. Chronic inflammation exerts a considerable impact in carcinogenesis, by inducing the deposition of a modified ECM tissue with qualitatively and quantitatively altered proteins in comparison with those detectable in normal pancreas. Such a condition is characterized by the progressive development of elevated tensional resistance stresses and high compression forces, both in intracellular and in extracellular compartments, and is associated with the perturbation of homeostasis [
30]. This process causes progressive changes in tissue architecture and spatial organization of this organ and induces an increase in its stiffness. Tissue stiffness is now recognized as a risk factor for cancer development not only in pancreas, but also in other organs [
31,
32]. However, although these modifications of pancreatic tissue structure have been qualitatively described and increased stromal collagen content has been reported in PDAC [
33,
34], only a few studies have been focused to the quantitative assessment of the structure and the organization of stroma in this malignancy [
35,
36].